Menu Open
▽
△
Menu Close

> > > 【スタッフ紹介】堀田 勝幸

【スタッフ紹介】堀田 勝幸

【専門領域】
呼吸器悪性腫瘍、新薬開発

【略歴】
大学卒業後、呼吸器内科領域・腫瘍内科領域の診療や研究に従事
現在、岡山大学病院 新医療研究開発センター臨床研究部所属

【一言】
呼吸器内科診療を行っています。
また、がんを含めた臨床研究の院内外の推進・支援を行っています

【主な業績】

最近の業績（Pubmedへのリンク）

  1. ● Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K (Corresponding author), Kiura K; HER2-CS Network. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY). Chest. 2019;156:357-366.
  2. ● Oda N, Hotta K (Corresponding author), Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T,Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. A Phase II Trial of EGFR-TKI Readministration with Afatinib in Advanced Non-Small-Cell Lung Cancer Harboring a Sensitive Non-T790M EGFR Mutation: Okayama Lung Cancer Study Group Trial 1403. Cancer Chemother Phamacol. 2018;82:1031-1038.
  3. ● Hotta K (Corresponding author), Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K. A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer. J Thorac Oncol. 2018;13:273-279.
  4. ● Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K (Corresponding author), Kiura K. Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochem Biophys Res Commun. 2018;495:360-367.
  5. ● Kubo T, Fujiwara K, Hotta K (Corresponding author), Okada T, Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, Maeda T, Kozuki T, Fujimoto N, Ninomiya K, Takemoto M, Kanazawa S, Takigawa N, Tabata M, Tanimoto M, Ueoka H, Kiura K. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemother Pharmacol. 2016;78:769-74.
  6. ● Ninomiya K, Hotta K (Corresponding author), Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: The second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.Int J Clin Oncol. 2016;21:81-7.
  7. ● Hotta K (Corresponding author), Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: Systematic Review. Plos One. 2015;10:e0121211.
  8. ● Aoe K, Takigawa N, Hotta K (Corresponding author), Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer. 2014;50:2783-2790.
  9. ● Hotta K (Corresponding author), Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013;43:1115-1123.
  10. ● Hotta K (Corresponding author), Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N, Ichihara E, Reck M, Manegold C, Pilz L, Hisamoto-Sato A, Tabata M, Tanimoto M, Shepherd FA, Kiura K. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2013;79:20-26.
  11. ● Fujiwara Y, Hotta K (Corresponding author), Di Maio M, Kiura K, Takigawa N, Tabata M, Tanimoto M. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol. 2011;22:376-3

戻る